ST-246 Days 1 - 3 + ST-246 Days 11 - 13
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Orthopoxviral Disease
Conditions
Orthopoxviral Disease, Smallpox, Monkey Pox
Trial Timeline
Aug 1, 2008 → Oct 1, 2008
NCT ID
NCT00728689About ST-246 Days 1 - 3 + ST-246 Days 11 - 13
ST-246 Days 1 - 3 + ST-246 Days 11 - 13 is a phase 1 stage product being developed by SIGA Technologies for Orthopoxviral Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00728689. Target conditions include Orthopoxviral Disease, Smallpox, Monkey Pox.
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00728689 | Phase 1 | Completed |
Competing Products
1 competing product in Orthopoxviral Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ST-246 400 mg + ST-246 600 mg + Placebo | SIGA Technologies | Phase 2 | 25 |